Clinical trial
Open-Label, 48-Week Extension Study of Elvucitabine in Combination With…
NCT00380159 · Alexion Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00380159 |
|---|---|
| Title | Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A |
| Official title | An Open-Label, 48-Week Extension Study of Elvucitabine Administered In Combination With Background Antiretroviral Agents in Participants Who Have Completed 14 Days of Treatment in Protocol ACH443-014A. |
| Lead sponsor | Alexion Pharmaceuticals, Inc., Industry |
| Collaborators | Achillion, a wholly owned subsidiary of Alexion Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Human Immunodeficiency Virus (HIV)-1 Infection |
| Intervention type | Drug |
| Interventions | Elvucitabine, Lamivudine, Emtricitabine |
| Enrollment | 4 |
| Start date | Sep 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Jan 1, 2009 |
| First posted | Sep 25, 2006 |
| Last update posted | Aug 14, 2023 |
| Countries | Dominican Republic, Germany, Spain, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: